• Alexion Pharmaceuticals Inc. announced that its board of directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the board of directors, effective immediately. He succeeds David R. Brennan, who has led the company as interim CEO since December 2016. Dr. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, and a global leader in the development of therapies for orphan and underserved diseases in hematology, immunology and oncology.
• Impax Laboratories Inc. announced that its board of directors has appointed Paul M. Bisaro as Impax's president and Chief Executive Officer and a member of the company's board, effective March 27, 2017. Bisaro will succeed J. Kevin Buchi, who has served as interim president and CEO since December of 2016. Bisaro previously served as executive chairman of Allergan plc (formerly Actavis).